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Abstract 
Master thesis for the programme in Medicine, "Validation of the heart failure diagnosis in 
Sahlgrenska University Hospital in 2000 - 2012 and an examination of co-morbidities 
present" by Ann Reimstad, Institute of Medicine; Gothenburg, Sweden. Supervisor Maria 
Schaufelberger.  
Background: Heart failure (HF) is a complex clinical syndrome, characterized by a variety of 
symptoms. Patients with HF are often old and have several co-morbidities. HF is a common 
disease with high mortality and morbidity, and with a large impact on quality of life. 
Therefore, diagnostic accuracy is important.  
Aim: To validate the HF diagnosis in patients hospitalized in Sahlgrenska University Hospital 
in Gothenburg under 2000- 2012, and also to examine whether co-morbidities may affect the 
validity of the diagnosis. 
Method: All patients hospitalized with the diagnosis of HF in Sahlgrenska University Hospital 
in 2000- 2012 were identified (27 517 patients). 1 100 patients were randomly selected and 
studied. Their diagnosis was validated according to the European Society of Cardiology 
(ESC) diagnostic guidelines. The co-morbidities studied were ischemic heart disease (IHD), 
diabetes mellitus (DM), hypertension, hyper- and hypothyreosis, asthmatic or chronic 
obstructive pulmonary disease (COPD), kidney failure, cardiomyopathy, atrial flutter-/ 
defibrillation, systemic inflammatory disease and drug-/ alcohol abuse.  
Results: Finally, 136 patients were excluded, mainly due to incomplete information or 
missing records. The validation of the HF diagnosis in the population studied (964 patients) 
were definite in 62.1 %, probable in 32.3 % and miscoded in 5.6 % of cases. No significant 
difference was found in the validity of the diagnosis when comparing the subgroups of co-
morbidities to the whole study population.  
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Conclusions: The overall validity of the HF diagnosis was 94.4 % which is quite high, and in 
line with earlier validation studies.  
Keywords: Heart failure, validation, diagnosis, co-morbidities 
Introduction  
The prevalence of heart failure (HF) in Sweden is approximately 2 - 3 % (1-3). The diagnosis 
causes high costs for society,  estimated to be around 2 % of the total healthcare budget, with 
75 % related to hospital care (1, 2). The 5- year mortality rate of HF exceeds many common 
types of cancer (4, 5). From time of diagnosis 50 % of the patients will die within 4 years, and 
for patients diagnosed with severe HF more than 50 % will die within one year (6). Chronic 
HF causes a large impact on the function and quality of life for the individuals who are 
suffering from the disease (7, 8).  
Clinical presentation and pathophysiology 
HF is a clinical syndrome which is caused by an underlying structural abnormality or function 
of the heart. This leads to an insufficient ability to deliver oxygen to the tissues of the body 
and results in a variety of symptoms. The most typical symptom of HF is exercise-induced 
dyspnea or dyspnea at rest, including ortopnea. Other common symptoms are fatigue, weight 
gain and ankle swelling, as well as palpitations. Weight gain and edema are caused by 
excessive fluid in the body due to a failed ability of the heart to maintain a proper blood flow. 
Severe, acute HF can due to fluid retention also cause pulmonary edema which leads to 
serious and sometimes fatal respiratory distress. HF is characterized by altered hemodynamics 
as well as an imbalance in other parts of the body, e.g. kidneys and the endocrine system (9, 
10). The severity of symptoms and function in a patient can be classified according to the 
New York Heart Association (NYHA) classification scale (fig. 1). HF can preferably be 
divided into systolic and diastolic HF. In recent years, it has been established how to diagnose 
diastolic dysfunction.  
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Figure 1. New York Heart Association (NYHA) classification of functional capacity in patients with cardiac 
disease. Source: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-
Heart-Failure_UCM_306328_Article.jsp 
 
Co-morbidities 
There is always an underlying cause of HF and most common are ischemic heart disease 
(IHD) and long-term hypertension. Other causes are damage of the heart valves, 
cardiomyopathy, myocarditis, diabetes mellitus (DM), amyloidosis, endocrine or 
inflammatory diseases or arrhythmia of the heart, e.g. atrial fibrillation. Many of these 
diseases may not just be the cause of but can also co-exist with HF, i.e. co-morbidities, and it 
is often difficult to confirm exactly what is the underlying cause of HF and what is just a co-
morbidity.   
Hypertension, IHD, DM, hyper- and hypothyreosis, asthmatic or chronic obstructive 
pulmonary disease (COPD), kidney failure, cardiomyopathy, atrial flutter-/ defibrillation, 
systemic inflammatory disease and drug-/ alcohol abuse are common co-morbidities to HF. 
Earlier studies has shown that these co-morbidities may affect the prognosis and as we 
hypothesized, how to set the diagnosis (11-15). Therefore it is important to validate the HF 
diagnosis in the aspect of co-morbidities. For example, symptoms in lung disease such as 
Class 
Functional Capacity: How a patient with cardiac disease feels during physical 
activity 
I 
Patients with cardiac disease but resulting in no limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or 
anginal pain. 
II 
Patients with cardiac disease resulting in slight limitation of physical activity. 
They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnea or anginal pain. 
III 
Patients with cardiac disease resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnea or anginal pain. 
IV 
Patients with cardiac disease resulting in inability to carry on any physical activity 
without discomfort. Symptoms of heart failure or the anginal syndrome may be 
present even at rest. If any physical activity is undertaken, discomfort increases. 
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COPD may be similar to those of HF. This might affect how the diagnosis of HF is set. These 
different conditions requires substantially different treatment, and therefore it is important that 
the diagnosis is correct, in order to avoid inadequate treatment strategies. DM may also affect 
how to set the HF diagnosis, since HF patients with DM has been shown to have diastolic HF 
in a higher extent than others (11), and diagnostic criteria for diastolic HF has been very 
complicated until recently. Regarding the validation of the HF diagnosis according to co-
morbidities, there are very few earlier studies. 
Diagnostic methods 
When a patient shows symptoms consistent with HF the patient is usually investigated with an 
electrocardiogram (ECG) which is easily accessed and associated with a low cost. Also the 
possibility to measure the natriuretic peptide BNP/ NT-proBNP in blood has made it easier to 
investigate the diagnosis as well, mainly as a tool to rule out HF in the early stages of 
investigation (16).  
Echocardiography (ECHO) is the most specific tool for diagnosing HF and should be 
performed in the next step of investigation. The ECHO may also give information about the 
etiology. Ejection fraction (EF) is the most used tool when assessing left ventricle, and heart 
function (17). The EF is the amount of blood that leaves the left ventricle in each contraction 
in relation to the total amount of blood in the left ventricle during diastole (18). An EF more 
than 50 % is considered to be normal (6). As mentioned, HF can be divided into systolic and 
diastolic HF. In systolic HF or HF-REF (HF with reduced ejection fraction) systolic 
dysfunction can be measured when performing ECHO (usually defined as an EF below 40-45 
%). In diastolic HF or HF-PEF (HF with preserved ejection fraction) the EF may be normal or 
slightly abnormal (45- 55 %) (6). HF-REF was defined already in the first European Society 
of Cardiology (ESC) HF guidelines from 1995. HF-PEF or diastolic HF is mentioned in the 
guidelines from 1995 and 2001 but were not defined until the 2005- update. The diagnosis of 
HF-PEF is more complex and difficult to set than HF-REF (19, 20). For the definition of HF-
8 
 
REF and HF-PEF according to the current ESC guidelines see fig. 2. The guidelines published 
in 2012 states that patients with an EF 35- 50 % represents a "grey area" and could be 
diagnosed as HF-PEF but only after exclusion of other causes (6).    
 
Figure 2. Diagnosis of heart failure. HF = heart failure; HF-PEF = heart failure with ‘preserved’ ejection 
fraction; HF-REF = heart failure and a reduced ejection fraction; LA = left atrial; LV = left ventricular; LVEF = 
left ventricular ejection fraction.  
a
Signs may not be present in the early stages of HF (especially in HF-PEF) and 
in patients treated with diuretics. Source: McMurray, J. J., et al. (2012). "ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and 
Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart 
Failure Association (HFA) of the ESC." Eur Heart J 2012; 33(14): 1787-1847.  
Diagnostic criteria 
In Sweden it is established to use the diagnostic criteria set in the HF guidelines from the 
ESC. In a study made in 2008 93 % of the cardiologists in Sweden told they were aware of 
the ESC guidelines and 92 % of those reported they continually follow the guidelines (21). 
The guidelines have changed during the years, and there are four versions of the guidelines 
that have been used clinically during 2000-2012. The first ESC guidelines were published in 
1995, and have been updated and re-published in 2001, 2005, 2008 and 2012. Other 
established criteria regarding how to diagnose HF are the Framingham criteria, the Boston 
criteria and the Carlson criteria. The Framingham criteria demand two major criteria or one 
major and two minor criteria fulfilled, where the criteria describes typical and more rare 
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symptoms of HF respectively (22). The Boston criteria classifies the diagnosis of HF definite 
or possible when over a certain amount of points, which are gathered from the medical 
history, chest X-ray and the physical examination (22). The Carlson criteria are a variation of 
the Boston criteria (23). 
Description of the ESC guidelines  
The ESC guidelines of 1995; 
The first guidelines published in 1995 suggest that the diagnosis of HF requires typical 
symptoms of HF as well as objective evidence of cardiac dysfunction, preferably ECHO. If 
the diagnosis is questionable improved symptoms after treatment aimed at HF (e.g. a diuretic 
or an ACE inhibitor) strengthens the diagnosis. Characteristic symptoms are said to be 
breathlessness/ dyspnea, ankle swelling or fatigue. Typical signs are preferably peripheral 
edema, hepatomegaly and a raised venous pressure (e.g. jugular vein distension) but also 
tachycardia, a third heart sound and pulmonary rales. E.g. if a patient has typical symptoms 
and signs (peripheral edema, a raised venous pressure and in addition a displaced apex beat as 
well as a third heart sound), the diagnosis of HF could be made with some confidence, even 
without an ECHO. According to the guidelines ECHO is the golden standard, and should be 
executed whenever HF is suspected and EF should be assessed. A normal ECG strongly 
opposes the diagnosis. Chest X-ray should preferably be executed, primarily in order to 
exclude pulmonary disease as a cause of symptoms. Diastolic dysfunction is mentioned, but 
how to set the diagnosis of diastolic HF is not stated. In blood works, the natriuretic peptide 
ANP is mentioned and stated to support the diagnosis if elevated; or oppose the diagnosis if 
not in an untreated patient (24).  
The ESC guidelines of 2001; 
The guidelines published in 2001 are similar to those of 1995, and also claims that symptoms 
of HF as well as objective evidence (preferably ECHO) is necessary for diagnosis. Response 
to treatment for HF, like before, supports the diagnosis if present. Typical symptoms are, as in 
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previous guidelines, breathlessness, ankle swelling and fatigue. Typical signs mentioned are 
peripheral edema, a raised venous pressure and hepatomegaly, but also tachycardia, a third 
heart sound, pulmonary rales and cardiac murmur. If a patient has typical symptoms and 
multiple signs of HF (e.g. pitting edema, a raised venous pressure, a displaced apex beat and a 
third heart sound), the diagnosis of HF could be made with some confidence. As before, a 
normal ECG strongly opposes the diagnosis. Chest X-ray should be part of the investigation 
when suspecting HF, primarily for excluding pulmonary causes of symptoms. 
ECHO is still considered the golden standard to demonstrate cardiac dysfunction in an 
objective manner. Diastolic dysfunction is again mentioned, and diagnostic criteria have been 
proposed by the European Study Group on Diastolic Heart Failure (25). However, though no 
universally accepted criterion for diastolic HF existed at that time, no further criteria are 
mentioned in the guidelines (26).   
The ESC guidelines of 2005;  
As before, typical symptoms and objective evidence are required for the diagnosis of HF. 
Response to treatment aimed at HF strengthens the diagnosis. The method for showing 
objective evidence is still preferably a performed ECHO. Now it is clearly stated that cardiac 
dysfunction can be both systolic and diastolic. Diagnostic criteria for diastolic dysfunction 
(diastolic HF) are now established. To set the diagnosis appropriate signs or symptoms are 
required, as well as evidence of abnormal left ventricular relaxation, diastolic stiffness or 
diastolic distensibility, and a normal or mildly abnormal LVEF (left ventricular ejection 
fraction) of ≥45-50 %.   
The natriuretic peptides BNP and NT- proBNP are first discussed in the 2005 guidelines. A 
normal concentration in an untreated patient makes HF unlikely and may determine whether 
to go further in investigations in a patient with symptoms, e.g. in primary care (27).  
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The ESC guidelines of 2008; 
In the guidelines published in 2008, symptoms of HF and objective evidence of an 
abnormality of cardiac function and structure is required, as well as clinical signs. Clinical 
signs to look for are peripheral edema, pulmonary rales, tachycardia, tachypnoea, 
hepatomegaly, raised jugular venous pressure and pleural effusion. Symptoms required are 
dyspnea, fatigue, tiredness or ankle swelling. The objective evidence is specified as 
cardiomegaly on chest X-ray, a third heart sound, cardiac murmur, abnormality on ECHO or 
raised levels of natriuretic peptides in blood sample. Clinical response to treatment may help 
set the diagnosis in uncertain cases. 
The part on diastolic HF (HF-PEF) is also extended. To recognize HF-PEF / diastolic 
dysfunction on an ECHO it is crucial to look for abnormal filling patterns. It is specified in 
the guidelines that there are three types of abnormal filling patterns; one pattern of "impaired" 
myocardial relaxation, one pattern of restrictive filling in the left ventricle (LV), and an 
intermediate pattern between the first two (impaired relaxation and restrictive filling). Hence, 
the diagnosis HF-PEF can be set under the circumstances that; apart from the fact that 
symptoms or signs of HF must be present, there is evidence of diastolic dysfunction and a 
normal or mildly abnormal LV systolic function on ECHO.  
Natriuretic peptides can also be used as objective evidence when setting the diagnosis. An 
elevated NT-proBNP >2000 ng/L makes the HF diagnosis likely. On the contrary, a BNP 
<100 ng/L or NT-proBNP <400 ng/L makes the diagnosis of HF unlikely. 
To summarize; in the new guidelines of 2008 in comparison to before, clinical signs are 
mandatory but the objective finding does not necessarily have to be a performed ECHO (28). 
Validation  
It is important to validate the diagnosis of HF in order to be able to decide whether trends in 
prevalence and incidence are true or not (2, 29). The trends may be influenced by praxis when 
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diagnosis is set, and this may of course affect the true figures. Earlier studies have shown low 
accuracy when diagnosing HF in elderly and obese and for  patients with DM and atrial flutter 
(11, 30, 31). Many studies are old and few are made in Scandinavia, or made in an inpatient 
setting. Therefore, further studies are needed within the field.  
Aim  
The aim of this study was to validate the diagnosis of HF according to the ESC guidelines in 
patients hospitalized with HF in Sahlgrenska University Hospital in 2000-2012. In addition to 
this, the aim was also to examine whether co-morbidities may affect the validity of the HF 
diagnosis.  
Material and Methods   
Study population 
The Sahlgrenska University Hospital is located in Gothenburg and includes three different 
hospitals; the Östra hospital, the Mölndal hospital and the Sahlgrenska hospital. The city of 
Gothenburg has 500 000 inhabitants (32) but the Sahlgrenska University Hospital to some 
extent serves the population in the western part of southern Sweden 
(Västragötalandsregionen) with 1.6 million inhabitants (33). Between 2000 - 2012 27 517 
patients were hospitalized with a HF diagnosis within the Sahlgrenska University Hospital.  
Of those, 1 100 hospitalizations (called index hospitalization dates) with unique patients were 
randomly selected, identified from the digital record system Melior by a statistician using the 
SAS version 9.3. All patients had been discharged with the diagnosis of HF; code I50 
according to the WHO International Classification Diseases (ICD 10). Half of the patients 
(550) had HF as the primary diagnosis and the other half (550) had the diagnosis in any 
contributory position. After exclusions, 964 patients were finally included in the study. The 
most common reason for exclusions was missing data and errors in the selection process 
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(table 3). Missing data was either due to fractioned hospital care (part of admission on other 
hospitals outside of Gothenburg) or due to the fact that the records needed could not be found 
despite extensive search in the medical records archives. More patients with HF in 
contributory position were excluded than with HF as primary diagnosis, resulting in 534 
patients included with HF as primary diagnosis and 430 included with HF as diagnosis in 
contributory position (table 2).  
Collection of data 
This was a retrospective study. Four medical students collected the material by going through 
medical records for symptoms and signs of HF and appropriate investigations (ECHO, blood 
samples, chest X-ray, ECG, magnetic resonance imaging (MRI) and radionuclide 
angiography) and whether symptomatic improvement after treatment occurred or not, using a 
specific composed form, see appendix. The form was made to associate to the content in the 
guidelines from the ESC. The data collection started in January 2013.  
If the medical records could not be found in the digital system (Melior) it was searched for in 
the record- and microfilm archives. The reports on ECHO examinations were, if not available 
in Melior, searched for in the archives of the Clinical Physiology departments of the different 
hospitals. Symptoms, signs and investigations were collected from the emergency room notes 
throughout the whole hospitalization including the epicrisis. When collecting information 
about co-morbidities it could be sampled both from the admission notes and from the 
diagnostic codes in the epicrisis. The findings of the physical examination were collected 
primarily from the admission date, and were not noted as a clinical sign if only mentioned, 
e.g. in history-taking in the admission note.    
For the patients with HF as primary diagnosis all data was collected from the index 
hospitalization. For patients with HF in contributory position information about signs, 
symptoms and investigations were sampled from the first hospitalization or other first 
14 
 
mentioning in the records for HF. Chest X-ray was collected up to a year before this 
hospitalization. The age of the patient were always noted from the index hospitalization date.  
Diagnostic methods 
Chest X-ray/ Computer tomography of the thorax;  
From the radiology report of the chest X-ray / computer tomography of the thorax (CT-
thorax) signs of HF were registered. Redistribution, pulmonary congestion, pulmonary edema 
and pleural fluid were noted as signs of HF as well as if the radiologist clearly reported that 
HF was present. In patients hospitalized in 2009-2012, the presence of cardiomegaly on chest 
X-ray was also noted as this was considered objective evidence when validating the diagnosis 
according to the guidelines of 2008.  
Echocardiography (ECHO); 
The ECHO report with the lowest EF before or during the index hospitalization was used for 
validation of the diagnosis. In this study, we considered an ECHO with an EF <45% as 
pathological. In all cases where ECHO had pathological findings but an EF >45 %, the case 
was reviewed by an experienced cardiologist. If the ECHO report stated "diastolic 
dysfunction" HF-PEF was considered present, if "diastolic dysfunction" was not mentioned 
but there were still abnormal findings that can be present in diastolic dysfunction; e.g. left 
ventricular hypertrophy, enlarged left atrium or high diastolic filling pressure, the case was 
judged by two experienced cardiologists on whether diastolic dysfunction was present or not. 
Also, if a patient had an earlier pathological ECHO performed (e.g. reduced EF or dilation of 
the heart) but during the index hospitalization the ECHO was normal, it was assessed by two 
experienced cardiologists for definite validation.   
Electrocardiogram (ECG); 
If more than one ECG was performed during the index hospitalization the first one was used 
for validation. For patients with HF in contributory positions, the first ECG taken in the 
hospitalization when HF was first diagnosed was used.  
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The ECG was assessed pathologic or non-pathologic considering the rhythm, QRS-width, 
presence of Q-waves, ST/T-changes or left bundle branch block. An ECG with none of the 
above abnormalities, and with sinus-rhythm, was considered non-pathologic. All ECG that 
appeared non- pathologic was assessed by one, and in case of doubt two experienced 
cardiologists before assessed as normal.  
Natriuretic peptides;  
For the patients with the HF diagnosis in contributory position the blood sample with the 
highest value of BNP or NT-proBNP before or during the index hospitalization was collected. 
This also applies to patients with HF as primary diagnosis, but not to all. For the first 400 
patients studied, the latest value before the index hospitalization was collected, and for the 
rest of the patients with HF as primary diagnosis the highest value was collected.  
Validation 
After collecting the data the diagnosis was validated according to ESC guidelines in clinical 
use at time of index hospitalization by four medical students and an experienced cardiologist 
and defined as definite, probable or miscoded. If they could not make a final decision another 
two experienced cardiologists were consulted. 
During the years studied, the ESC guidelines were updated four times. The first guidelines 
were published in 1995, with updates in 2001, 2005, 2008 and 2012. We anticipated that it 
takes up to a year before an updated version of the guidelines is in clinical use. For example, 
if the index hospitalization date was in 2005, the guidelines used were the ones from 2001; 
and if the hospitalization date was in 2006 the guidelines used were the ones from 2005.  
The diagnosis was sorted into groups as definite, probable or miscoded for each patient 
validated. An EF of ≤45 % was assessed as pathological. To be defined as definite, the patient 
had to report symptoms, show findings during physical examination and objective finding of 
cardiac dysfunction (preferably ECHO). There are some differences between the ESC 
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guidelines of the different years. The guidelines of 1995, 2001 and 2005 require symptoms 
(dyspnea, peripheral edema and/ or fatigue) in the medical history, an objective finding 
(preferably an ECHO) and, in uncertain cases response to treatment directed towards HF 
support the diagnosis. In the guidelines from 2008, symptoms and an objective finding of 
cardiac dysfunction (abnormality on the ECHO, cardiomegaly, third heart sound, cardiac 
murmurs or raised level of natriuretic peptides) as well as clinical signs of HF are mandatory. 
Thus, the objective finding of cardiac dysfunction does not have to be a performed ECHO, 
according the guidelines of 2008. For a summary of the guidelines used in this study, see table 
1. 
In this study the validity of the HF diagnosis was also examined according to co-morbidities. 
The patients were divided into subgroups according to co-morbidity, and then the groups were 
compared to the whole study population to see if the validity was affected by the patient´s co-
morbidities.  
To ensure validation was made in a similar way by all four medical students involved in the 
project, 20 patients were picked from previous material and validated once again, in this part 
of the study. 10 patients with HF diagnosis in main and 10 patients with HF diagnosis in 
contributory position were randomly selected by a statistician and again validated to ensure 
inter-observer accuracy (table 7).  
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Table 1. Diagnostic assessment according to the European Society of Cardiology (ESC) guidelines. 
 1995 2001 2005 2008 
 Supports if present/ 
Opposes if normal 
or absent 
Supports if present/ 
Opposes if normal 
or absent 
Supports if present/ 
Opposes if normal 
or absent 
Supports if present/ 
Opposes if normal 
or absent 
Appropriate 
symptoms 
+++*/--- +++*/-- +++*/--- ++*/-- 
Appropriate signs +++/- +++/- +++/- ++*/- 
Response to 
treatment 
+++/--- +++/--- +++/--- +++/-- 
Pathological ECG /--- /--- /--- ++/-- 
Cardiac 
dysfunction on 
imaging 
+++*/--- +++*/--- +++*/--- +++**/-- 
Chest X- ray +/- +/- +/- +++/- 
Natriuretic 
peptides 
n/a + (if elevated)  
/--- 
+ (if elevated)  
/--- 
+++ (if elevated)  
/--- 
Abbreviations: +/- of some importance; ++/-- of particular/ considerable importance; +++/--- of major 
importance. * Necessary for definite diagnosis. ** Considered an objective evidence of cardiac dysfunction. 
ECG = electrocardiogram; ESC = European society of cardiology. This assessment adapted from the heart 
failure diagnostic guidelines edited by the ESC in 1995, 2001, 2005 and 2008. 
Co-morbidities 
In the form it was noted if the patient apart from HF suffered from IHD, DM, hypertension, 
hyper- or hypothyroidism, pulmonary disease (asthmatic or obstructive/ COPD), kidney 
failure, cardiomyopathy, atrial flutter /-fibrillation, systemic inflammatory disease or drug- / 
alcohol abuse. Information about drug- / alcohol abuse was not sampled in the first 422 
patients but was added in the last 542 patients. Lupus, rheumatic arthritis, polymyalgia 
rheumatica, temporal arteritis/ vasculitis and Morbus Bechterew were considered as systemic 
inflammatory diseases. Patients were considered to suffer from kidney failure if it was 
expressed in the admission note or as a diagnostic code in the epicrisis (as for all other co-
morbidities). For patients with HF in contributory position the patient was also considered to 
suffer from kidney failure if an elevated serum-creatinine was present (>100 mmol/L). The 
first available serum-creatinine from the hospitalization was sampled.  
For all the patients co-morbidities were collected from the index hospitalization.  
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Ethics   
Revealing the identity of the patients involves a violation of integrity. Due to the retrospective 
design of this study, no approval from the patients was collected. However, each patient was 
given a code, which was continually used through the process of collecting data. The identity 
and social security number of the patient was strictly kept in a separate file, only able to be 
accessed by the few persons involved in the study. All material with personal information was 
kept within the hospital, in a locked compartment. Only patient data relevant for the study was 
viewed. Approval to access patient information and - data was collected from the manager of 
each clinic involved in the study. As knowledge about the epidemiology of HF is very 
important, e.g. for planning on how to use the health care budget in the most cost-effective 
way in the future, we believe that the violation of integrity of the patients involved in the 
study could be motivated. Also, all results in this report are presented as group data, and no 
individual patient can therefore be able to recognize him- or herself in hind-sight. 
The study was approved by the Ethical review board of the University of Gothenburg with 
registration number: 2011-588/08/10.  
Statistical methods  
Descriptive statistics was used to present baseline characteristics and determine percentages, 
mean scores, standard deviations (SD) and range. Since the variables studied were normally 
distributed, comparisons between groups were assessed with t-test for continuous variables, or 
Pearson Chi-square test and Generalized Linear Models were used when comparing 
dichotomous variables. For comparing categorical values frequencies was used. Analyses 
were conducted using the SPSS Advanced Statistics for Windows statistical package, version 
21 (SPSS Inc., Chicago, IL, USA). A two-sided p-value < 0.05 was considered statistically 
significant.  
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Results 
Participants and exclusions  
The total study population included 964 patients, 50.5 % women and 49.5 % men (table 2). Of 
the patients 55.4 % had the HF diagnosis in primary position and 44.6 % in any contributory 
position. The mean age of the study population was 78.7, and the median age was 81 years (at 
time of index hospitalization). The age ranged from 19 to 100 years. A total of 776 patients 
were hospitalized in an internal medicine clinic and another 188 in a cardiology clinic (80.5 % 
and 19.5 %, respectively). 
Table 2. Study population.  
Characteristic  Number of patients (% of total) 
Age (years)   
- Mean (SD) 78.7 (11.1)  
- Median (range) 81 (19-100)  
Men   477 (49.5) 
Women  487 (50.5) 
Diagnostic position:   
- Primary position  534 (55.4) 
- Contributory position  430 (44.6) 
Sahlgrenska Hospital  354 (36.8) 
Mölndal Hospital  192 (19.9) 
Östra Hospital  418 (43.4) 
Hospitalized in internal medicine 
clinic 
 776 (80.5) 
Hospitalized in cardiology clinic  188 (19.5) 
Validated according to:    
- ESC guidelines of 1995  210 (21.8) 
- ESC guidelines of 2001   328 (34.0) 
- ESC guidelines of 2005  179 (18.6) 
- ESC guidelines of 2008  247 (25.6) 
   
Total  964 (100) 
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Table 3. Exclusions. Exclusions according to category. 
Reason for exclusion Number of patients 
Errors in selection process 54 
- Diagnosis other than HF 11 
- Clinic other than medicine or cardiology 35 
- Missing digit in social security number 7 
- Age < 16  1 
  
Information missing 60 
- Part of hospitalization in another hospital 12 
- Medical record not found 37 
- Patient unable to leave history information*  11 
  
Hospitalization due to elective procedure 22 
  
Excluded, contributory position 113 
Excluded, primary diagnosis 23 
Total excluded 136 
* dementia or other cognitive impairment, intoxication, unconsciousness, aphasia 
Validity 
The validity for the whole study population was definite in 62.1 % of cases (599 patients), 
probable in 32.3 % (311 patients) and miscoded in 5.6 % of cases (54 patients) (table 4). 
Thus, the diagnosis was definite or probable in 94.4 % of cases (fig. 3).  
Co-morbidities  
The most frequent co-morbidities in the study population were IHD, atrial defibrillation/ - 
flutter and hypertension (table 5). Drug - or alcohol abuse was present in 8.3 % of cases (out 
of 542 patients). The least common of the co-morbidities registered was hyperthyreosis, 
which was present in 0.6 % of the cases (6 patients). Cardiomyopathy was present in 4.7 % of 
the patients.  
No significant difference was found when comparing the validity between the whole study 
population and the different subgroups of co-morbidities (p-value varied from 0.094 to 1.0). 
In this analysis age and sex were thought to be possible confounding factors. Therefore, when 
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analyses were made for the subgroups of co-morbidities they were included as confounding 
factors. This did not alter the results. 
Investigations 
ECHO was performed in 74 % of the whole study population. Out of the patients with 
cardiomyopathy, 44 out of 45 patients had an ECHO performed (98 %). For patients with 
pulmonary disease (obstructive and/ or asthmatic) ECHO was performed in 78 % of cases, for 
IHD in 79 %, for DM in 81 %, and for patients with inflammatory systemic diseases and drug/ 
alcohol abuse in 80 % and 89 %, respectively (table 6).  
Of the whole study population 94 % had an ECG performed (907 patients). Of those, 791 
patients had an assessment made in our study whether the ECG was pathological or not. Of 
those 95 % (752 patients) had a pathological ECG. An MRI or radionuclide angiography was 
performed in 0.2 % of patients, respectively. 
In 93.5 % of patients a chest X-ray/ CT thorax had been performed. Of those, 66 % showed 
signs of HF on the examination. Another 20.2 % of patients had a BNP/ NT-proBNP taken. 
The mean value of NT-proBNP was 7003 ng/ L (SD 8511), with a range from 0 to >35 000 
ng/ L.  
Inter-observer validation 
The result from the inter-observer validation, were 20 patients were re-validated in this part of 
the study, was 89.5 % (table 7). 
 
 
 
 
 
 
 
22 
 
Table 4. Result of validation. Results of validation separated according to each guideline year and in total. All 
numbers in n (%).  
ESC guidelines Definite Probable Miscoded Definite and 
probable 
Total  
1995 119 (56.7) 78 (37.1) 13 (6.2) 197 (93.8) 210 (21.8) 
2001 178 (54.3) 123 (37.5) 27 (8.2) 301 (91.8) 328 (34.0) 
2005 98 (54.8) 72 (40.2) 9 (5.0) 170 (95.0) 179 (18.6) 
      
2008 204 (82.6) 38 (15.4) 5 (2.0) 242 (98.0) 247 (25.6)  
      
Validity all 
years except 
2008 
395 (55.1) 273 (38.1) 49 (6.8) 668 (93.2) 717 (74.4) 
      
Total validity 599 (62.1) 311 (32.3) 54 (5.6) 910 (94.4) 964 (100) 
      
  
 
 
Figure 3. Total result of validation. The whole study population included. 
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Table 5. Co- morbidities in the study population. 
Co- morbidities examined Female sex 
(%) 
Mean age 
(year) 
Number of 
patients (%) 
IHD 46.6 79.1 483 (50.1) 
Diabetes mellitus 46.3 76.6 216 (22.4) 
Hypertension 54.1 79.4 449 (46.6) 
Hyperthyreosis 100 77.7 6 (0.6) 
Hypothyreosis 81.0 81.7 79 (8.2) 
Pulmonary disease (asthmatic/obstructive) 48.4 78.0 159 (16.5) 
Kidney failure 41.8 78.8 153 (15.9) 
Cardiomyopathy 44.4 65.7 45 (4.7) 
Atrial defibrillation/ flutter 47.4 80.4 483 (50.1) 
Inflammatory systemic disease  71.2 78.3 73 (7.6) 
Drug or alcohol abuse (n=542) 28.9 62.4 45 (8.3) 
    
Total patients 50.5 78.7 964 
Abbreviations: IHD = ischemic heart disease. 
 
Table 6. Performed echocardiogram (ECHO) in subgroups of co-morbidities in comparison to the whole 
study population.  
Co- morbidity ECHO performed (%) P- value 
IHD 78 0.002 
Diabetes mellitus 81 0.021 
Hypertension 75 0.768 
Hypothyreosis 66 0.080 
Pulmonary disease (asthmatic/ 
obstructive) 
78 0.275 
Kidney failure 83 0.008 
Cardiomyopathy 98 <0.001 
Atrial flutter/defibrillation 74 0.658 
Inflammatory systemic disease 80 0.332 
Drug- /alcohol abuse 89 ¹ 0.030 
Total study population 74  
Abbreviations: IHD = ischemic heart disease. ¹ Only in 542 cases this co-morbidity was registered.  
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Table 7. Inter-observer accuracy. In numbers if not otherwise stated. 
  Number of patients 
Primary diagnosis Total patients 527 
Re-validated  10 
Validated with same result  9 
Different validation result  1 (probable instead of miscoded) 
   
Contributory diagnosis  Total patients 437 
Re-validated  10 
Validated with same result  9 
Different validation result  1 (probable instead of definite) 
   
Total viewed  20 
Different validation result  2 
Total validation accuracy (%)  89.5 
Discussion    
Main findings in relation to consensus in the field  
In this study the validity of the HF diagnosis was assessed as definite in 62.1 % and as 
probable in 32.3 %; overall a validity of 94.4 %. The patients assessed as probable had shown 
symptoms and/or objective findings typical for HF, and in several cases also had 
investigations performed supporting the diagnosis but did not fulfill all requirements for a 
definite diagnosis. Mostly, an ECHO was missing. Only 5.6 % were assessed as miscoded 
which is in line with earlier studies and is considered to show a high validity, i.e. a high 
diagnostic accuracy. In a study made by Ingelsson and co-workers in 2005 the diagnosis of 
HF was classified as definite in 82 %, as questionable in 16 % of cases, and only in 2 % as 
miscoded. All men, 50 years of age in year 1970 - 1974 in Uppsala County, Sweden, were 
invited to participate in a study. Of totally 2 322 men 321 were diagnosed with HF during a 
median follow-up time of 29 years. Only patients undergoing hospital care were included 
hence the patient data was collected from the Swedish hospital discharge register. Thus, the 
study population is both small and narrow, and does not include women. In the study by 
Ingelsson and co-workers the ESC diagnostic guidelines were used for validation, but were 
not strictly followed, thus other findings than ECHO could be used as objective evidence of 
HF, e.g. a pathological chest X- ray (34). In another study made by Khand and co-workers in 
Scotland in 2005, 791 patients discharged with HF or atrial fibrillation were included. The 
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patients were identified from the national hospital discharge register in the United Kingdom. 
They found that out of 330 patients diagnosed with HF, 87 % were jointly assessed as HF 
(definite, probable or possible) and 13 % were miscoded. They validated the diagnosis 
according to the ESC guidelines of 2005 (31). Thus, their result shows a lower level of 
validity than ours. Blackburn and co-workers made a validation study of HF from 
administrative hospital records in Saskatchewan, Canada, including 466 patients discharged 
with HF. They used the Framingham and Carlson criteria for validation. The result was that 
74 % and 63.9 % of the patients met the criteria for the diagnosis of HF, respectively. This is 
line with the result in our study, as 62.1 % of the patients were assessed as definite HF, and 
we consider that equal fulfilled Framingham and Carlson criteria (23). Another validation 
study was made by Fonseca and co-workers in Portugal in 2008, where they looked at the 
validity in patients with HF as a discharge or death diagnosis. The patients were assessed as 
definite, possible or miscoded according to the ESC guidelines. It included 234 patients in 
total and shows a validity of 96 %. This is in line with our validation result (30).  
In addition, the study by Fonseca also investigated patients discharged with conditions 
associated to HF (e.g. coronary artery disease and atrial fibrillation among others). When 
viewing these patients, it was concluded that the HF diagnosis was underestimated in 21 % of 
cases (30). This suggests that HF is often under-diagnosed. Similar results were also found in 
the previously mentioned study by Khand. They found that the diagnosis of HF had 
incorrectly not been given in between 16 and 36 % the group discharged with atrial 
fibrillation (31). This study supports the results of Fonseca, that HF may often be under-
diagnosed. This might be a problem in Swedish hospitals as well, although it has not been 
investigated in our study as we have only examined patients with a HF diagnosis. On the 
contrary, we investigated the validity of the HF diagnosis, and thus if a possible over-
diagnosis was present. 
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In this study we wanted to investigate if co-morbidities affect the validity of the HF diagnosis. 
No significant differences were seen between the whole study population and the different co-
morbidity groups, in relation to validity in this study. One hypothesis, mentioned in the 
introduction, was that the symptoms of pulmonary disease such as COPD could be similar to 
those of HF and affect the diagnostic precision. Our results did not support this hypothesis.  
We also investigated to what extent ECHO was performed in the groups of co-morbidities 
(table 6). ECHO was performed to a significantly higher degree in patients with 
cardiomyopathy, kidney failure, IHD, DM and drug-/alcohol abuse. Patients with 
cardiomyopathy had ECHO performed to a high extent (98 %). This could be due to that 
cardiomyopathy is a diagnosis of exclusion and therefore an ECHO must have been 
performed before this diagnosis is set. Use of ECHO in the different groups might be due to 
other causes, e.g. the age or sex of the patient or which clinic the patient was admitted to. The 
unequal use of ECHO in the subgroups could have affected the validity of the HF diagnosis in 
the different subgroups of co-morbidities, as ECHO is an important tool of investigation. 
Therefore, the unequal use of ECHO could have shaded possible differences when comparing 
the validity of the subgroups to the validity of the whole study population. Interestingly, the 
patients with pulmonary disease, which we hypothesized would have had a ECHO performed 
to a higher extent due to differential diagnostic difficulties, did not have an ECHO performed 
to a higher extent compared to whole study population. Therefore our hypothesis could not be 
confirmed by our results.  
In our study we found that the most common co-morbidities were IHD, hypertension and 
atrial fibrillation. In a recent study by Lund and co-workers hypertension and atrial 
fibrillation/-flutter as well as numerous non-cardiovascular co-morbidities were associated 
with HF-PEF (14). In another recent study Le Corvoisier and co-workers found high 
prevalence of co-morbidities in patients with acute decompensated HF in their study of 555 
patients admitted to emergency departments in five French hospitals. The most frequent co-
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morbidities were hypertension, atrial fibrillation/-flutter and DM (12). Another study was 
made by van Deursen and co-workers, and they also found that co-morbidities are highly 
prevalent in HF patients. Their study contained 3 226 patients within Europe, and the co-
morbidities studied were DM, hyper- and hypothyroidism, stroke, COPD, sleep apnea, 
chronic kidney disease (CKD) and anemia. They found that 74 % of the patients had at least 
one co-morbidity; the most frequent were CKD, DM and anemia (15). The most frequently 
occurring co-morbidities associated with HF mentioned in the introduction were thus common 
both in our study as well as in these mentioned studies. This shows that our data is 
representable for HF in the general hospital population. Notably anemia mentioned in the last 
study was not examined in our study and could possibly have been interesting to examine.  
To our knowledge there are no earlier studies made where the diagnosis of HF has been 
validated according to co-morbidities.  
Methodological considerations  
The validation process of this study is also important to discuss. ECHO is considered golden 
standard when setting the diagnosis of HF, but was not performed in all patients in this study. 
The diagnosis could still be considered definite, in cases validated according to the guidelines 
of 2008 and in two cases validated according to guidelines from 2005 and 2008 where EF was 
determined from MRI and radionuclide angiography instead of ECHO. A normal ECG makes 
the diagnosis of HF less likely according to the ESC guidelines of all years in this study (table 
1). Of the patients, 95 % (791 was assessed in this matter) had a pathological ECG. Normal 
level of natriuretic peptides in blood sample makes HF unlikely in an untreated patient 
according to the guidelines of 2005 and 2008 (after the general introduction of the sampling 
of natriuretic peptides). However, only around 20 % of the patients in our study population 
had a BNP/NT-proBNP taken because it was not used routinely until the latest years of this 
study. All in all, when taking all these measurements in account, the HF diagnosis in our 
study was validated according to guidelines even in absence of an ECHO. This study includes 
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patients with HF as a primary diagnosis as well as patients with HF as a contributory 
diagnosis. When validating the patients with HF in contributory position we went back to the 
first available hospitalization when the diagnosis was set, to collect the data. Therefore it may 
be claimed that those patients were validated in the same way as patients with HF as primary 
diagnosis. Even so, the diagnosis was always validated in reference to the index 
hospitalization date for all patients and at that time the patients treating physician had all the 
old information, therefore we used all this information too in the validation. 
The study population in this study is large in comparison to earlier validation studies (23, 30, 
31, 34, 35) as it includes 964 patients, which is a major strength of this study. As mentioned, 
there are several guidelines available when validating the diagnosis of HF. The ESC 
guidelines are elaborated and updated by European expertise in cardiology according to 
current knowledge. Also, the awareness and use of the ESC guidelines in Sweden is proved 
high (21).  
This study included patients admitted to three different hospitals in Gothenburg located in 
different areas. Two hospitals, Mölndal and Östra are primary hospitals whereas one, the 
Sahlgrenska hospital is both a primary hospital for about 250 000 citizens of Gothenburg and 
a tertiary hospital for the Västra Götaland region (1.6 million inhabitants). This, as well as the 
number of patients studied, makes it possible, to some extent to generalize our data to the 
whole of Sweden. However, patients with a primary diagnosis of HF are seldom referred to a 
tertiary hospital, just in case of need for left ventricular assist or heart transplant. In case of 
HF as secondary diagnosis the figures are more difficult to estimate. In cases where 
Sahlgrenska was used as a tertiary hospital 12 cases were excluded due to missing 
information in the records. This, as for all exclusion processes, may have caused a selection 
bias as we could not control or account for which patients were excluded due to missing data.  
In this study 136 patients were excluded. A majority had HF as a contributory diagnosis (83 
%). This could be explained by the difficulty to find the records from the first hospitalization 
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date for HF as a diagnosis which sometimes was several years back. Early records were 
harder to find as they were not digitalized which resulted in exclusion due to missing records 
(table 3). This resulted in a higher number of exclusions in this group than for the patients 
with HF as a main diagnosis. As mentioned above, this may have caused a selection bias.  
Another limitation of this study is that the study population only consists of patients that were 
hospitalized and not patients diagnosed in primary care. According to Zarrinkoub and co-
workers, 35 % of all HF patients in Stockholm are managed only in primary health care (2). 
Therefore the in-hospital population examined in this study can be assumed to have a more 
severe disease than the over-all HF population, which may have affected the validation.   
Also, when analyzing the material in this study, the validity of the HF diagnosis in the groups 
of co-morbidities was compared to the validity of the whole study population. Another 
statistical analyze that could have been made would have been to compare the validity of the 
HF diagnosis in the subgroups of co-morbidities to each other. Even so, the analyze made for 
the most part does answer the aim of this study; to examine whether co-morbidities may affect 
the validity of the HF diagnosis. 
Yet another limitation of this study could be that there have been four medical students who 
collected the material. To ensure inter-observer accuracy regular meetings with the group of 
medical students and supervisor were held during the data collection process. During these 
meetings it was discussed how to interpret data when reading the patient medical records. In 
addition, 20 patients out of the total 964 were revalidated in this part of the study to ensure 
inter-observer accuracy. The result was 89.5 % accuracy (table 7). Only one patient was 
assessed probable instead of miscoded. The other patient was considered probable instead of 
definite (still considered having the diagnosis of HF).  
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Conclusions 
In total, the validity of the HF diagnosis was high, thus only 5.6 % of the cases were assessed 
as miscoded. No significant difference in validity was found when comparing the groups of 
co-morbidities to the whole study population, thus indicating that the diagnostic accuracy is 
not affected by the patient´s co-morbidities. However, there was a significant difference in to 
what extent the groups of co-morbidities had a performed ECHO compared to the whole 
study population. This, as well as the fact that the study population had a performed ECHO in 
only 74 % of cases, may indicate that a wider use of ECHO may even further improve the 
validity of the HF diagnosis.       
Populärvetenskaplig sammanfattning på svenska*   
Hjärtsvikt är en allvarlig sjukdom som drabbar ca 2 % av Sveriges befolkning. Symtomen vid 
hjärtsvikt är bland andra andfåddhet, trötthet och bensvullnad. Dödligheten är jämförbar med 
några av de vanligaste cancersjukdomarna, med en dödlighet på 50 % inom fyra år. För 
patienter med svår hjärtsvikt är dödligheten 50 % inom ett år. Hjärtsvikt kan t.ex. uppstå efter 
genomgången hjärtinfarkt. Andra orsaker kan vara högt blodtryck, hjärtrytmrubbning eller 
diabetes. Ofta har hjärtsviktspatienter flera olika sjukdomar samtidigt, s.k. komorbiditeter. De 
komorbiditeter, d.v.s. sjukdomar, vi tittat på i den här studien är ischemisk hjärtsjukdom 
(d.v.s. hjärtinfarkt och kärlkramp), högt blodtryck, diabetes, sköldkörtelsjukdom, njursvikt, 
hjärtrytmrubbning, inflammatorisk systemsjukdom, lungsjukdom, hjärtmuskelsjukdom och 
alkohol- och drogberoende sjukdom. Syftet med studien var dels att titta på validiteten för 
hjärtsviktsdiagnosen för hela studiepopulationen, dels för grupper av patienter med olika 
komorbiditeter. Detta är viktigt för att kunna bedöma om uppgifter om sjukdomens förändring 
över tid är verklig, eller om diagnossättningen vid hjärtsvikt är påverkad t.ex. av lokal praxis.  
Under 2000- 2012 vårdades 27 517 patienter på Sahlgrenska universitetssjukhuset i Göteborg 
med diagnosen hjärtsvikt. 1 100 patienter valdes slumpmässigt ut i den här studien och 
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slutligen granskades 964 patienter. Information om patientens symtom och utförda 
undersökningar såsom röntgenundersökningar, hjärtultraljud och laborationsprover samlades 
in. Sedan validerades hjärtsviktsdiagnosen utifrån Europeiska hjärtföreningens riktlinjer. 
Diagnosen bedömdes utifrån riktlinjerna som definitiv, trolig eller felaktig. 
Resultatet blev att 94,4 % av patienterna i studien bedömdes ha en definitiv eller trolig 
hjärtsviktsdiagnos medan 5,6 % av patienterna bedömdes att felaktigt ha fått en 
hjärtsviktsdiagnos.  
Vi fann också att det inte fanns några skillnader i diagnossättningen när vi jämförde 
grupperna av patienter med olika komorbiditeter med hela studiepopulationen. Däremot 
kunde man se att vissa grupper av patienter oftare var utredda med hjärtultraljud, jämfört med 
hela studiepopulationen. Detta gällde för patienter med ischemisk hjärtsjukdom, diabetes, 
njursvikt, hjärtmuskelsjukdom och med alkohol- eller drogberoendesjukdom. Hjärtultraljud 
underlättar diagnossättningen av hjärtsvikt, och varför vissa grupper i högre grad än andra har 
hjärtultraljud utfört skulle t.ex. kunna bero på patienternas ålder eller om patienten vårdats 
inom en hjärtklinik eller inte, något som skulle kunna utredas vidare i framtida 
forskningsstudier.  
Acknowledgements 
My appreciation goes to Associate Professor Maria Schaufelberger for her guidance during 
this research project. I would also like to thank Professor Annika Rosengren for her valuable 
input on study design and assessment of some challenging patient cases.  
I would like to thank statistician Tatiana Zverkova Sandström for her time spent working on 
the randomization process of the patient database.  
32 
 
My appreciation also goes to medical students Sofia Ekestubbe, Mattias Schaufelberger and 
Simon Hultgren for their help in data collection and study design, and to medical student 
Josefin Henninger for help in proofreading this report.  
References   
 
1. Paren P, Schaufelberger M, Bjorck L, Lappas G, Fu M, Rosengren A. Trends in 
prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. European journal 
of heart failure. 2014;16(7):737-42. 
2. Zarrinkoub R, Wettermark B, Wandell P, Mejhert M, Szulkin R, Ljunggren G, et al. The 
epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. European journal 
of heart failure. 2013;15(9):995-1002. 
3. Mejhert M, Persson H, Edner M, Kahan T. Epidemiology of heart failure in Sweden--a 
national survey. European journal of heart failure. 2001;3(1):97-103. 
4. Stewart S, Ekman I, Ekman T, Oden A, Rosengren A. Population impact of heart failure 
and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 
2004). Circulation Cardiovascular quality and outcomes. 2010;3(6):573-80. 
5. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends 
in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 
1987-2003 from the Swedish Hospital Discharge Registry. European heart journal. 2009;30(6):671-8. 
6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force 
for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of 
Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European 
heart journal. 2012;33(14):1787-847. 
7. Falk H, Ekman I, Anderson R, Fu M, Granger B. Older patients' experiences of heart 
failure-an integrative literature review. Journal of nursing scholarship : an official publication of 
Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau. 2013;45(3):247-55. 
8. Falk K, Patel H, Swedberg K, Ekman I. Fatigue in patients with chronic heart failure - a 
burden associated with emotional and symptom distress. European journal of cardiovascular nursing 
: journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 
2009;8(2):91-6. 
9. Braunwald E. Heart failure: pathophysiology and treatment. American heart journal. 
1981;102(3 Pt 2):486-90. 
10. Braunwald E. Heart failure. JACC Heart failure. 2013;1(1):1-20. 
11. Go YY, Allen JC, Chia SY, Sim LL, Jaufeerally FR, Yap J, et al. Predictors of mortality in 
acute heart failure: interaction between diabetes and impaired left ventricular ejection fraction. 
European journal of heart failure. 2014;16(11):1183-9. 
12. Le Corvoisier P, Bastuji-Garin S, Renaud B, Mahe I, Bergmann JF, Perchet H, et al. 
Functional status and co-morbidities are associated with in-hospital mortality among older patients 
with acute decompensated heart failure: a multicentre prospective cohort study. Age and ageing. 
2014. 
13. Sankaranarayanan R, Kirkwood G, Visveswariah R, Fox DJ. How Does Chronic Atrial 
Fibrillation Influence Mortality In The Modern Treatment Era? Current cardiology reviews. 2014. 
14. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, et al. Association 
between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with 
preserved ejection fraction. European journal of heart failure. 2014;16(9):992-1001. 
33 
 
15. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, et al. Co-
morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. 
European journal of heart failure. 2014;16(1):103-11. 
16. Kelder JC, Cowie MR, McDonagh TA, Hardman SM, Grobbee DE, Cost B, et al. 
Quantifying the added value of BNP in suspected heart failure in general practice: an individual 
patient data meta-analysis. Heart (British Cardiac Society). 2011;97(12):959-63. 
17. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340(8811):88-92. 
18. Ejection Fraction Heart Failure Measurement. The American Heart Association 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejecti
on-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp: American Heart Association; Aug 
4,2014. 
19. Argulian E, Messerli FH. Misconceptions and Facts about 'Diastolic' Heart Failure. The 
American journal of medicine. 2014. 
20. Becher PM, Lindner D, Fluschnik N, Blankenberg S, Westermann D. Diagnosing heart 
failure with preserved ejection fraction. Expert opinion on medical diagnostics. 2013;7(5):463-74. 
21. Erhardt L, Komajda M, Hobbs FD, Soler-Soler J. Cardiologists' awareness and 
perceptions of guidelines for chronic heart failure. The ADDress your Heart survey. European journal 
of heart failure. 2008;10(10):1020-5. 
22. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. 
The relationship between left ventricular systolic function and congestive heart failure diagnosed by 
clinical criteria. Circulation. 1988;77(3):607-12. 
23. Blackburn DF, Shnell G, Lamb DA, Tsuyuki RT, Stang MR, Wilson TW. Coding of heart 
failure diagnoses in Saskatchewan: a validation study of hospital discharge abstracts. Journal of 
population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et 
de la pharamcologie clinique. 2011;18(3):e407-15. 
24. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the 
European Society of Cardiology. European heart journal. 1995;16(6):741-51. 
25. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. 
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with 
normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of 
the European Society of Cardiology. European heart journal. 2007;28(20):2539-50. 
26. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart 
failure. European heart journal. 2001;22(17):1527-60. 
27. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for 
the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task 
Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of 
Cardiology. European heart journal. 2005;26(11):1115-40. 
28. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, 
et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task 
Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European 
Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) 
and endorsed by the European Society of Intensive Care Medicine (ESICM). European journal of heart 
failure. 2008;10(10):933-89. 
29. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart 
failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. 
European heart journal. 2014;35(1):25-32. 
30. Fonseca C, Sarmento PM, Marques F, Ceia F. Validity of a discharge diagnosis of heart 
failure: implications of misdiagnosing. Congestive heart failure (Greenwich, Conn). 2008;14(4):187-
91. 
31. Khand AU, Shaw M, Gemmel I, Cleland JG. Do discharge codes underestimate 
hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. 
European journal of heart failure. 2005;7(5):792-7. 
32. http://www4.goteborg.se/prod/G-
info/statistik.nsf/34f4087fac810b1ac1256cdf003efa4b/2acd96ba76aa5dc6c1257b350045bf6c!Open
Document Nov 19, 2014. 
34 
 
33. http://www.vgregion.se/sv/Vastra-Gotalandsregionen/startsida/Om-Vastra-
Gotalandsregionen/Regionorganisationen/Regionkansliet/Ekonomi/Nyckeltal/ Nov 19, 2014. 
34. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in 
a hospital discharge register. European journal of heart failure. 2005;7(5):787-91. 
35. Mard S, Nielsen FE. Positive predictive value and impact of misdiagnosis of a heart 
failure diagnosis in administrative registers among patients admitted to a University Hospital cardiac 
care unit. Clinical epidemiology. 2010;2:235-9. 
  
35 
 
Appendix   
Kod: 
Sjukhus och klinik för epikris:                          Kön: M / K                 
□ Huvuddiagnos: □ Bi-diagnos:    Ålder vid validering: 
                Första diagnostillfälle, år: 
Valideringsår: Vårdtid:          Avliden (idag): Ja / Nej / Okänt 
 
Anamnestiska uppgifter 
Trötthet: Ja / Nej / Okänt                                                   Dyspné: Ja / Nej / Okänt 
Viktuppgång: Ja / Nej /Okänt                                             Hosta:    Ja / Nej / Okänt
Bensvullnad: Ja / Nej /Okänt                                             Ortopné: Ja / Nej /Okänt 
 
Övriga diagnoser:  
□ Ischemisk hjärtsjukdom        □ Diabetes mellitus                 □ Hypertoni 
□ Hyperthyreros                       □ Hypothyreos                        □ Astma/KOL                            
□ Njurinsufficiens, inkomst-kreatinin…….   
□ Kardiomyopatier                  □ FF/FFL □ Inflammatorisk systemsjukdom 
□ Missbruk             Övrigt…………………………………………………….. 
 
Statusfynd 
□ Halsvenstas □ Perkussionsdämpning □ Blåsljud 
□ Perifera ödem □ Lungrassel/krepitationer □ Takykardi >90 
□ Leverförstoring □ Takypnè > 20 □ Tredje ton 
□ Ascites □ Cyanos  
 
Genomförda undersökningar och svar 
UCG utfört: Ja / Nej           Datum…………………..   Rytm:…………………… 
EF:……… %                         □ VK-dilatation (med ord), diameter…….. mm 
□ VK-hypertrofi (med ord)      □ Lungvensreversering (med ord)           
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□ Klaffel:.........................................................................................................................   
□ Decelerationstid < 150 ms □ S/D kvot < 1 □ E/É 8-15 □ E/É >15 
□ Patologisk E/A-kvot (med ord) □ Pseudonormaliserad E/A-kvot (med ord) 
E/A-kvot:……. 
□ Relaxationsstörning i vä kammare (med ord) 
□ Diastolisk dysfunktion (med ord) 
Vä förmak: □ > 40 ml/m2 □ Måttligt eller kraftigt förstorat (med ord) 
Vä förmak yta……… cm2 
□ Hö förmak dilatation □ Hö kammar dilatation 
Hö förmak yta……… cm2 
BNP/NT-proBNP (ng/l): >2000 / >900 / 400-900 / <400 / Ej taget 
BNP/NT-proBNP:…….. ng/l 
Sviktbild vid lungröntgen/CT thorax: Ja / Nej / Ej utfört  
 
EKG: Ja/Nej      Rytm: SR/FF/PM-rytm/Övrigt    QRS-bredd:……ms 
□ Patologiskt EKG 
□ LBBB □ RBBB      □ Patologisk Q-våg  □ VK-hypertrofi  
□ Pat. R-vågsprogression □ Förlängd QTC-tid  □ ST-förändringar 
□ T-förändringar 
Hjärtscintigrafi: Ja* / Nej            MR-hjärta: Ja* / Nej 
 
Positivt svar på behandling : Ja / Nej / Okänt 
 
Övriga kommentarer:  
*Om ”ja” ovan, ange vad undersökningen visade här:
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